RECRUITING

Stroke Rate in Patients With Blunt Cerebrovascular Injury (BCVI) Treated With Oral Acetylsalicylic Acid (ASA) 81 mg Versus ASA 325 mg (BASA).

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to compare difference between Aspirin 81 mg and Aspirin 325 mg in preventing strokes in patients with head and neck vessels injury. The main questions it aims to answer are: * If Aspirin 81 mg efficacy in prevention of stroke in patients with head and neck vessels injury is not lower than and Aspirin 325 mg. * If rate of hemorrhagic complications in patients with head and neck vessels injury taking Aspirin 81 mg is not higher than patients that take Aspirin 325 mg.

Official Title

Pilot, Non-masked, Randomized Clinical Trial for Evaluation of Stroke Rate in Patients With Blunt Cerebrovascular Injury (BCVI) Treated With Oral Acetylsalicylic Acid (ASA) 81 mg Versus ASA 325 mg (BASA).

Quick Facts

Study Start:2024-12
Study Completion:2025-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05868525

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age ≥18
  2. * All patients with blunt cerebrovascular injury are diagnosed by computed tomography angiography (CTA) upon admission
  1. * Age \<18
  2. * Pregnant women
  3. * No enteral route access for Aspirin administration
  4. * Patients who are on Heparin drip or other full dose anticoagulation when BCVI diagnosed
  5. * Patients who are on other Anti-Platelets aside from Aspirin when BCVI diagnosed
  6. * Patients with BCVI grade 5 injury based on Biffl classification
  7. * Presence of any contraindication or history of allergy to Aspirin
  8. * Patient with the diagnosis of acute stroke at the time of BCVI diagnosis matching the injured vessel territory on imaging
  9. * Patients with acute spinal trauma that needs surgical intervention

Contacts and Locations

Study Contact

Maryam B Tabrizi, M.D
CONTACT
(909) 558-4286
MTabrizi@llu.edu
Sina Asaadi, M.D
CONTACT
(412) 539-7088
sasaadi@llu.edu

Study Locations (Sites)

Loma Linda University Medical Center
Loma Linda, California, 92354
United States

Collaborators and Investigators

Sponsor: Loma Linda University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-12
Study Completion Date2025-12

Study Record Updates

Study Start Date2024-12
Study Completion Date2025-12

Terms related to this study

Keywords Provided by Researchers

  • Blunt cerebrovascular injury
  • BCVI
  • Carotid artery
  • Vertebral Artery
  • Internal Carotid Artery

Additional Relevant MeSH Terms

  • Blunt Cerebrovascular Injury